Results 261 to 270 of about 1,512,902 (358)

Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery [PDF]

Tengfei Ren, Yuexi Mi, Jingjing Wei, Xiangyuan Han, Xingxiu Zhang, Qian Zhu, Tong Yue, Wenhao Gao, Xudong Niu, Cuiyan Han, Bing Wei   +10 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

DTLCDR: A target-based multimodal fusion deep learning framework for cancer drug response prediction

Jie Yu, Cheng Shi, Yiran Zhou, Ningfeng Liu, Xiaolin Zong, Zhenming Liu, Liangren Zhang   +6 more
openalex   +1 more source

Polyamidoamine Dendrimers: Brain-Targeted Drug Delivery Systems in Glioma Therapy [PDF]

Xinyi Yan, Qi Chen
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer. [PDF]

Future Oncol
Li Y, Xu Z, Li Y, Jiang T, Meng F, Fu J, Huang L, Wang F, Wang X, Wang F.   +9 more
europepmc   +1 more source

Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease [PDF]

Ruben Y. Gabriëls, Anne M. van der Waaij, Matthijs D. Linssen, Michael Dobosz, Pia Volkmer, Sumreen Jalal, Dominic J. Robinson, Marcela A. Hermoso, Marjolijn N. Lub–de Hooge, Eleonora A. Festen, Gürsah Kats‐Ugurlu, Gerard Dijkstra, Wouter B. Nagengast   +12 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies. [PDF]

J Adv Res
Sun J, Lou L, Zhu C, Chen P, Tang G, Gu M, Xia S, Dong X, Zhang ZM, Gao L, Yao SQ, Xiao Q.   +11 more
europepmc   +1 more source